Surya K. De

Great Ormond Street Hospital for Children NHS Foundation Trust — United Kingdom

Chemistry · Physical Sciences

35h-index4.0kcitations222works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemical Synthesis and Reactions(60), Melanoma and MAPK Pathways(34), Multicomponent Synthesis of Heterocycles(26), Chemical Synthesis and Analysis(26), Synthesis and biological activity(21)

Publications222 total

Contributors
Elsevier eBooks·2025
Supervised Machine Learning to Identify Hospital Inpatients Needing a Change of Antibiotic Therapy in Real Time: Preclinical Diagnostic Evaluation and Feasibility Study
Open Forum Infectious Diseases·2025Open Access
Inavolisib: A Selective Inhibitor of Mutant PI3Kα for the Treatment of Breast Cancer
Oncology Advances·2025· 1 citedOpen Access
Capivasertib: First Approved AKT inhibitor for the Treatment of Patients with Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry·2024· 4 cited
Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome
Frontiers in Pharmacology·2024· 8 citedOpen Access
Non-ATP Site Inhibitors and Bi-dentate Inhibitors
Drug design and discovery·2024
An Overview of Protein Kinase Inhibitors
Drug design and discovery·2024Open Access
Covalent Inhibitors of MAP Kinases
Drug design and discovery·2024
Biological Roles of MAP Kinases
Drug design and discovery·2024
ATP-Competitive Inhibitors of MAP Kinases
Drug design and discovery·2024
Drug Design and Discovery
2024· 71 citedOpen Access
Spatial Heterogeneity and Pandemic Dynamics: Geospatial Insights from Kolkata During Post-Lockdown COVID-19 Spread and Management
Springer geography·2024
Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor forTreating Relapsed or Refractory Mantle Cell Lymphoma in Adults
Current Medicinal Chemistry·2023· 17 cited
New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease
Current Medicinal Chemistry·2023· 1 cited
Novel Pyrazino[2,3-b] Pyrazines as mTOR Kinase Inhibitors forTreating Cancer and other Diseases
Current Medicinal Chemistry·2023· 1 cited
Novel Pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as ProteinKinase C Inhibitors for Treating Diseases
Current Medicinal Chemistry·2023
Pyrazolo[4,3-H]quinazolines as Cyclin-dependent Kinase Inhibitorsfor Treating Cancer
Current Medicinal Chemistry·2023· 1 cited
Discovery of Novel Cysteine Protease Inhibitors for the Treatment ofCoronavirus (COVID-19)
Current Medicinal Chemistry·2023· 2 citedOpen Access
Novel Arcyriaflavin-A Derivatives as PIM Kinase Inhibitors for Treating Cancer
Anti-Cancer Agents in Medicinal Chemistry·2023· 1 cited
First Approval of Elacestrant as a Selective Estrogen ReceptorDegrader for the Treatment of Metastatic Breast Cancer
Current Medicinal Chemistry·2023
page 1 of 12Next →

Frequent Co-authors

Maurizio Pellecchia(23), Richard A. Gibbs(13), Elisa Barile(12), John L. Stebbins(9), Bainan Wu(7), Li‐Hsing Chen(6), Megan Riel‐Mehan(6), Ze’ev A. Ronai(6), Vida Chen(6), Thomas Machleidt(5), Aras Emdadi(5), Angela Purves(4), Russell Dahl(4), Yongmei Feng(4), Jesús Vázquez(3), Jason Cellitti(3), Paul B. Fisher(3), Ria Murphy(3), Marzia Scortegagna(3), Marcus Bosenberg(3)